12 Month Price Forecast For AEON
Distance to AEON Price Forecasts
AEON Price Momentum
๐ค Considering AEON Biopharma (AEON)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 11, 2025 5:38 PM UTC
AEON Analyst Ratings & Price Targets
Based on our analysis of 1 Wall Street analyst, AEON has a bullish consensus with a median price target of $5.00 (ranging from $5.00 to $5.00). Currently trading at $0.13, the median forecast implies a 3,749.1% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Douglas Tsao at HC Wainwright & Co., projecting a 3,749.1% upside. Conversely, the most conservative target is provided by Douglas Tsao at HC Wainwright & Co., suggesting a 3,749.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AEON Analyst Consensus
AEON Price Target Range
Latest AEON Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AEON.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Oct 1, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $5.00 |
Aug 14, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $5.00 |
Jul 10, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $6.00 |
May 30, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $6.00 |
May 15, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $6.00 |
May 6, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $18.00 |
Apr 17, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $18.00 |
Aug 18, 2023 | HC Wainwright & Co. | Douglas Tsao | Buy | Initiates | $18.00 |
Stocks Similar to AEON Biopharma, Inc.
The following stocks are similar to AEON Biopharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
AEON Biopharma, Inc. (AEON) Financial Data
AEON Biopharma, Inc. has a market capitalization of $10.39M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of N/A.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

AEON Biopharma, Inc. (AEON) Company Overview
About AEON Biopharma, Inc.
Develops botulinum toxins for medical conditions.
AEON Biopharma operates as a clinical stage biopharmaceutical company, focusing on the development of botulinum toxins. The company generates revenue by advancing its drug candidates through clinical trials, with potential future income from product sales upon successful commercialization.
The company's lead product, ABP-450, has completed a Phase 2 study for cervical dystonia and is currently in ongoing trials for chronic and episodic migraine, as well as other conditions like gastroparesis and PTSD. AEON Biopharma is headquartered in Irvine, California.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
5
CEO
Mr. Marc Forth
Country
United States
IPO Year
2023
Website
www.aeonbiopharma.comAEON Biopharma, Inc. (AEON) Latest News & Analysis
AEON Biopharma, Inc. received a notice from NYSE American for non-compliance with equity requirements due to a $32.1 million stockholders' deficit and reported losses in recent fiscal years.
AEON Biopharma's non-compliance with NYSE American's equity requirements raises concerns about its financial health, potentially impacting stock value and investor confidence.
AEON Biopharma, Inc. closed a public offering on January 7, 2025, raising approximately $20 million before expenses. The company focuses on developing a botulinum toxin complex under a biosimilar pathway.
AEON Biopharma's $20 million public offering enhances its financial position, potentially accelerating research and development, which could drive future growth and impact stock performance.
AEON Biopharma, Inc. (NYSE: AEON) has launched a public offering of units, which include shares of Common Stock and warrants to purchase Common Stock, as part of its biosimilar development strategy.
AEON Biopharma's public offering can dilute existing shares and signal capital needs, impacting stock price and investor sentiment. Its focus on a biosimilar pathway may attract interest in biotech growth potential.
AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
2 months agoThe company held a biosimilar advisory meeting with the FDA in Q3 2024, aligning on a 351(k) regulatory pathway for ABP-450 as a biosimilar to BOTOXยฎ.
Progress in the regulatory pathway for ABP-450 as a biosimilar to BOTOXยฎ could lead to market entry, potentially increasing revenue and market share for the company involved.
AEON Biopharma, Inc. (AEON) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
5 months agoAEON Biopharma, Inc. shows a hammer chart pattern signaling support after recent losses, alongside rising earnings estimate revisions, suggesting a potential trend reversal.
The hammer pattern signals potential support for AEON's stock, while rising earnings estimates suggest a possible trend reversal, indicating a favorable outlook for investors.
AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
5 months agoAEON Biopharma, Inc. (NYSE: AEON) will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference on September 11, 2024, at 1:30 PM ET.
AEON Biopharma's CEO presentation at a major investment conference may highlight key developments and attract investor interest, potentially impacting stock performance and market perception.
Frequently Asked Questions About AEON Stock
What is AEON Biopharma, Inc.'s (AEON) stock forecast for 2025?
Based on our analysis of 1 Wall Street analysts, AEON Biopharma, Inc. (AEON) has a median price target of $5.00. The highest price target is $5.00 and the lowest is $5.00.
Is AEON stock a good investment in 2025?
According to current analyst ratings, AEON has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.13. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for AEON stock?
Wall Street analysts predict AEON stock could reach $5.00 in the next 12 months. This represents a 3,749.1% increase from the current price of $0.13. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is AEON Biopharma, Inc.'s business model?
AEON Biopharma operates as a clinical stage biopharmaceutical company, focusing on the development of botulinum toxins. The company generates revenue by advancing its drug candidates through clinical trials, with potential future income from product sales upon successful commercialization.
What is the highest forecasted price for AEON AEON Biopharma, Inc.?
The highest price target for AEON is $5.00 from Douglas Tsao at HC Wainwright & Co., which represents a 3,749.1% increase from the current price of $0.13.
What is the lowest forecasted price for AEON AEON Biopharma, Inc.?
The lowest price target for AEON is $5.00 from Douglas Tsao at HC Wainwright & Co., which represents a 3,749.1% increase from the current price of $0.13.
What is the overall AEON consensus from analysts for AEON Biopharma, Inc.?
The overall analyst consensus for AEON is bullish. Out of 1 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $5.00.
How accurate are AEON stock price projections?
Stock price projections, including those for AEON Biopharma, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.